SCHEMBL264124

SCHEMBL264124

CC1(C)COCC1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23529 0.76
SCHEMBL24677915 0.75
SCHEMBL15626931 0.75
Ammonia Solution, Strong SCHEMBL17457516 0.73
SCHEMBL18480151 0.70 EPHX1 (0.35)
SCHEMBL7807411 0.70
SCHEMBL5259026 0.70
SCHEMBL3044058 0.70
SCHEMBL12682254 0.70
SCHEMBL23528 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11732261-B2 Selective antisense compounds and uses thereof IONIS PHARMACEUTICALS, INC. (US) 2023-08-22 US disclosed
US-20230056189-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF PATHOLOGIC PAIN ASSOCIATED WITH MALIGNANT GROWTH DISORDER DUKE UNIVERSITY 2023-02-23 US disclosed
US-20180028555-A1 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS IONIS PHARMACEUTICALS, INC. (US) 2018-02-01 US disclosed
US-20180010126-A1 ANTISENSE COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2018-01-11 US disclosed
US-20180010128-A1 OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAs Regulus Therapeutics Inc. (US) 2018-01-11 US disclosed
US-20170369880-A1 COMPOSITIONS COMPRISING ALTERNATING 2'-MODIFIED NUCLEOSIDES FOR USE IN GENE MODULATION IONIS PHARMACEUTICALS, INC. (US) 2017-12-28 US disclosed
US-9827263-B2 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations IONIS PHARMACEUTICALS, INC. (US) 2017-11-28 US disclosed
US-20170335322-A1 COMPOUNDS AND METHODS FOR THE MODULATION OF COMP IONIS PHARMACEUTICALS, INC. (US) 2017-11-23 US disclosed
US-20170327824-A1 SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2017-11-16 US disclosed
US-20170283804-A1 ANTISENSE COMPOUNDS AND USES THEREOF IONIS PHARMACEUTICALS, INC. (US) 2017-10-05 US disclosed
US-7875733-B2 Nucleosides; RNA interference; gene expression inhibition; for use in therapeutic, diagnostic, and research applications involving gene silencing ISIS PHARMACEUTICALS, INC. (US) 2011-01-25 US disclosed
US-20100324277-A1 OLIGOMERIC COMPOUNDS COMPRISING 4'-THIONUCLEOSIDES FOR USE IN GENE MODULATION ISIS PHARMACEUTICALS, INC. (US) 2010-12-23 US disclosed
US-7678895-B2 Antisense modulation of superoxide dismutase 1, soluble expression ISIS PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20090298174-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2009-12-03 US disclosed
US-20090291907-A1 Oligomeric Compounds And Compositions For Use In Modulation Of Small Non-Coding RNAs REGULUS THERAPEUTICS, LLC. (US) 2009-11-26 US disclosed
US-20090203896-A1 MODULATION OF SURVIVIN EXPRESSION ISIS PHARMACEUTICALS, INC. 2009-08-13 US disclosed
US-7339051-B2 Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) ISIS PHARMACEUTICALS, INC. (US) 2008-03-04 US disclosed
US-20080027019-A1 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN ISIS PHARMACEUTICALS, INC. (US) 2008-01-31 US disclosed
US-7220787-B2 Photoreactive hot-melt adhesive composition SEKISUI CHEMICAL CO., LTD. (JP) 2007-05-22 US disclosed
US-20070054869-A1 Antisense modulation of superoxide dismutase 1, soluble expression BIOGEN MA INC. 2007-03-08 US disclosed